SI2272873T1 - Protitelesa proti humanemu receptorju inzulinu podobnega rastnega faktorja i in njihova uporaba - Google Patents

Protitelesa proti humanemu receptorju inzulinu podobnega rastnega faktorja i in njihova uporaba

Info

Publication number
SI2272873T1
SI2272873T1 SI200432234T SI200432234T SI2272873T1 SI 2272873 T1 SI2272873 T1 SI 2272873T1 SI 200432234 T SI200432234 T SI 200432234T SI 200432234 T SI200432234 T SI 200432234T SI 2272873 T1 SI2272873 T1 SI 2272873T1
Authority
SI
Slovenia
Prior art keywords
receptor
growth factor
antibodies against
human insulin
against human
Prior art date
Application number
SI200432234T
Other languages
English (en)
Inventor
Yvo Graus
Erhard Kopetzki
Klaus-Peter Kuenkele
Olaf Mundigl
Paul Parren
Frank Rebers
Ralf Schumacher
De Winkel Jan Van
Vugt Martine Van
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2272873T1 publication Critical patent/SI2272873T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI200432234T 2003-07-10 2004-07-09 Protitelesa proti humanemu receptorju inzulinu podobnega rastnega faktorja i in njihova uporaba SI2272873T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03015526 2003-07-10
EP10180710.5A EP2272873B1 (en) 2003-07-10 2004-07-09 Antibodies against human insulin-like growth factor I receptor and uses thereof

Publications (1)

Publication Number Publication Date
SI2272873T1 true SI2272873T1 (sl) 2015-05-29

Family

ID=33560758

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432234T SI2272873T1 (sl) 2003-07-10 2004-07-09 Protitelesa proti humanemu receptorju inzulinu podobnega rastnega faktorja i in njihova uporaba

Country Status (29)

Country Link
US (3) US7579157B2 (sl)
EP (4) EP1959014B9 (sl)
JP (2) JP4276262B2 (sl)
KR (1) KR100795745B1 (sl)
CN (1) CN100453645C (sl)
AR (1) AR046071A1 (sl)
AT (2) ATE413454T1 (sl)
AU (3) AU2004256215B2 (sl)
BR (1) BRPI0412478B8 (sl)
CA (1) CA2532173C (sl)
CO (1) CO5640053A1 (sl)
CY (1) CY1116227T1 (sl)
DE (2) DE602004017614D1 (sl)
DK (3) DK1959014T5 (sl)
ES (3) ES2534638T3 (sl)
HK (1) HK1094713A1 (sl)
IL (1) IL172925A (sl)
MX (1) MXPA06000270A (sl)
MY (1) MY140209A (sl)
NO (2) NO339935B1 (sl)
NZ (1) NZ544455A (sl)
PL (3) PL2272873T3 (sl)
PT (3) PT1646720E (sl)
RU (2) RU2363706C2 (sl)
SG (1) SG129437A1 (sl)
SI (1) SI2272873T1 (sl)
TW (1) TWI290147B (sl)
WO (1) WO2005005635A2 (sl)
ZA (1) ZA200600181B (sl)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
ES2527871T3 (es) * 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP2322217A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
ES2356830T3 (es) * 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
CA2611149A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
CA2678008C (en) * 2005-06-17 2013-07-30 Imclone Systems Incorporated Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7807409B2 (en) * 2005-10-21 2010-10-05 Roche Palo Alto Llc Method for the recombinant expression of a polypeptide
CA2624685C (en) 2005-10-28 2014-06-03 Ulrich Goepfert Protein expression in rodent cells
CN101484587B (zh) * 2006-02-03 2014-02-12 英克隆有限责任公司 Igf-ir拮抗剂作为辅药用于***癌的治疗
KR101402592B1 (ko) * 2006-03-06 2014-06-17 에스케이바이오팜 주식회사 피록시캄-무기물 복합체를 포함하는 경피투여 조성물 및이를 이용한 패치시스템
KR101047207B1 (ko) 2006-03-09 2011-07-06 에프. 호프만-라 로슈 아게 항-약물 항체 분석
AU2007229554A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
EA200802061A1 (ru) * 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
US20080014203A1 (en) * 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN101460522B (zh) * 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
US20100041063A1 (en) 2006-09-12 2010-02-18 Ulrich Essig Anti-drug antibody assay
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) * 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EP2126565B1 (en) 2007-02-27 2011-10-26 F. Hoffmann-La Roche AG Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor
EP2129397B1 (en) * 2007-03-02 2018-10-31 Amgen, Inc. Methods and compositions for treating tumor diseases
US20100260766A1 (en) * 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
AU2008248780B2 (en) 2007-05-02 2013-01-31 F. Hoffmann-La Roche Ag Method for stabilizing a protein
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8314225B2 (en) * 2007-06-29 2012-11-20 Hoffman-La Roche Inc. Heavy chain mutant leading to improved immunoglobulin production
JP2010537985A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
EP2197490A2 (en) * 2007-08-28 2010-06-23 Biogen Idec MA, Inc. Compositions that bind multiple epitopes of igf-1r
EP2197421A1 (en) * 2007-08-31 2010-06-23 Amgen, Inc Solid-state protein formulation
ES2750254T3 (es) * 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
ES2532483T3 (es) 2007-12-15 2015-03-27 F. Hoffmann-La Roche Ag Ensayo de distinción
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20100261216A1 (en) 2007-12-21 2010-10-14 Bianca Eser Stability testing of antibodies
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
BRPI0919382A2 (pt) * 2008-09-26 2016-01-05 Roche Glycart Ag anticorpos bi-específicos anti-egfr/anti-igf-1r
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
CA2749354A1 (en) 2009-03-30 2010-10-14 F. Hoffmann-La Roche Ag A method for avoiding glass fogging
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AU2010309931B2 (en) 2009-10-19 2015-08-20 F. Hoffmann-La Roche Ag Non-cross-reactive anti IgG antibodies
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
ES2548533T3 (es) 2010-04-29 2015-10-19 Theradiag Sa Procedimientos para detectar anticuerpos contra un fármaco
SG194370A1 (en) 2010-06-07 2013-11-29 Amgen Inc Drug delivery device
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
EP2593142B8 (en) 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
CA2805564A1 (en) * 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
CN103068852B (zh) 2010-08-17 2016-04-20 弗·哈夫曼-拉罗切有限公司 抗人IgG1抗体
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
WO2012107416A2 (en) 2011-02-10 2012-08-16 Roche Glycart Ag Improved immunotherapy
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
BR112013020338A2 (pt) 2011-02-28 2016-10-18 Hoffmann La Roche proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
CN103502273A (zh) 2011-04-20 2014-01-08 罗氏格黎卡特股份公司 用于pH依赖性通过血脑屏障的方法和构建体
PT2699293T (pt) 2011-04-20 2019-05-21 Amgen Inc Aparelho de autoinjeção
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
MX2014002996A (es) 2011-09-23 2014-05-28 Roche Glycart Ag Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
AU2012322796B2 (en) 2011-10-14 2017-03-16 Amgen Inc. Injector and method of assembly
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
AU2013301582B2 (en) 2012-08-07 2018-09-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
LT2976117T (lt) 2013-03-22 2021-02-25 Amgen Inc. Purkštuvas ir surinkimo būdas
TWI653243B (zh) 2013-04-29 2019-03-11 赫孚孟拉羅股份公司 遏止ＦｃＲｎ結合之抗ＩＧＦ－１Ｒ抗體及其治療血管性眼疾之用途
JP2016528167A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトＦｃＲｎ結合改変抗体及び使用方法
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
EP3501575B1 (en) 2013-10-24 2021-12-01 Amgen Inc. Drug delivery system with temperature-sensitive-control
EP3789064A1 (en) 2013-10-24 2021-03-10 Amgen, Inc Injector and method of assembly
BR112016014969A2 (pt) 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
CA2945026C (en) 2014-05-07 2023-10-10 Amgen Inc. Autoinjector with shock reducing elements
CA2948003C (en) 2014-06-03 2023-06-27 Amgen Inc. Drug delivery system and method of use
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
JP2020509837A (ja) 2017-03-09 2020-04-02 アムジエン・インコーポレーテツド 薬剤送達装置のための挿入機構
LT3600491T (lt) 2017-03-28 2023-10-10 Amgen Inc. Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
EP3641857A1 (en) 2017-06-22 2020-04-29 Amgen Inc. Device activation impact/shock reduction
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing element for drug container and methods of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
EP3706830A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Drug delivery device with placement and flow sensing
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
US11208490B2 (en) 2018-03-05 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US11208489B2 (en) 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US20210128844A1 (en) 2018-07-24 2021-05-06 Amgen Inc. Delivery devices for administering drugs
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
AU2019347710A1 (en) 2018-09-24 2021-02-04 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
MA53818A (fr) 2018-10-05 2022-01-12 Amgen Inc Dispositif d'administration de médicament ayant un indicateur de dose
EP3866889A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Platform assembly process for drug delivery device
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
US20220031939A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
AU2020263289A1 (en) 2019-04-24 2021-09-16 Amgen Inc. Syringe sterilization verification assemblies and methods
EP4017560A2 (en) 2019-08-23 2022-06-29 Amgen, Inc Drug delivery device with configurable needle shield engagement components and related methods
WO2021158823A1 (en) * 2020-02-04 2021-08-12 Hznp Limited Methods for the treatment of scleroderma and related conditions
AU2022279223A1 (en) 2021-05-21 2023-10-19 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023122714A2 (en) * 2021-12-23 2023-06-29 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2023133561A1 (en) 2022-01-09 2023-07-13 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
DE69408541T2 (de) 1993-11-23 1998-08-06 Genentech Inc Kinaserezeptoraktivierungstest
US6417330B1 (en) * 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
PT1399483E (pt) 2001-01-05 2010-07-20 Pfizer Anticorpos contra o receptor do factor i de crescimento tipo insulina
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
CN100410275C (zh) 2002-01-18 2008-08-13 皮埃尔法布雷医药公司 新的抗igf-ir抗体及其应用
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006517581A (ja) 2003-02-13 2006-07-27 ファイザー・プロダクツ・インク 抗インスリン様増殖因子ｉ受容体抗体の使用
MXPA05009837A (es) * 2003-03-14 2005-12-05 Pharmacia Corp Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres.
ES2527871T3 (es) * 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos

Also Published As

Publication number Publication date
AU2008202949A1 (en) 2008-07-31
EP1959014A3 (en) 2009-01-14
DK2272873T3 (en) 2015-03-09
JP2009077709A (ja) 2009-04-16
EP2272873B1 (en) 2015-01-28
DE602004031988D1 (de) 2011-05-05
EP1646720A2 (en) 2006-04-19
AU2008207635B2 (en) 2008-11-20
BRPI0412478B1 (pt) 2020-04-14
MXPA06000270A (es) 2006-04-07
US7572897B2 (en) 2009-08-11
NZ544455A (en) 2008-12-24
PL2272873T3 (pl) 2015-06-30
ES2360454T3 (es) 2011-06-06
HK1094713A1 (en) 2007-04-04
ATE413454T1 (de) 2008-11-15
EP2243835A2 (en) 2010-10-27
CA2532173A1 (en) 2005-01-20
PT2272873E (pt) 2015-04-07
RU2363706C2 (ru) 2009-08-10
EP2243835A3 (en) 2010-11-10
EP1959014A2 (en) 2008-08-20
TWI290147B (en) 2007-11-21
US7579157B2 (en) 2009-08-25
KR100795745B1 (ko) 2008-01-17
PL1959014T3 (pl) 2011-08-31
AU2004256215A1 (en) 2005-01-20
JP2008538273A (ja) 2008-10-23
PT1959014E (pt) 2011-06-15
CO5640053A1 (es) 2006-05-31
JP4276262B2 (ja) 2009-06-10
KR20060054296A (ko) 2006-05-22
DK1959014T5 (da) 2011-06-06
EP1646720B1 (en) 2008-11-05
NO20161389A1 (no) 2016-09-02
SG129437A1 (en) 2007-02-26
US20080132686A1 (en) 2008-06-05
ZA200600181B (en) 2007-04-25
MY140209A (en) 2009-11-30
WO2005005635A3 (en) 2005-08-25
NO20056246L (no) 2006-02-09
AR046071A1 (es) 2005-11-23
AU2004256215B2 (en) 2008-07-17
JP4464450B2 (ja) 2010-05-19
DK1959014T3 (da) 2011-04-18
BRPI0412478B8 (pt) 2021-05-25
BRPI0412478A (pt) 2006-09-19
ES2534638T3 (es) 2015-04-27
RU2008126743A (ru) 2010-01-10
US20050008642A1 (en) 2005-01-13
PL1646720T3 (pl) 2009-04-30
DE602004017614D1 (de) 2008-12-18
RU2006103854A (ru) 2007-08-20
EP1959014B9 (en) 2011-12-28
EP2272873A3 (en) 2011-09-28
NO339935B1 (no) 2017-02-20
CA2532173C (en) 2013-11-12
CY1116227T1 (el) 2017-02-08
DK1646720T3 (da) 2009-01-05
IL172925A (en) 2013-07-31
AU2008207635A1 (en) 2008-09-25
CN1823163A (zh) 2006-08-23
PT1646720E (pt) 2008-12-26
CN100453645C (zh) 2009-01-21
ATE502959T1 (de) 2011-04-15
ES2360454T9 (es) 2012-02-16
ES2317020T3 (es) 2009-04-16
EP2272873A2 (en) 2011-01-12
AU2008202949B2 (en) 2008-09-25
IL172925A0 (en) 2006-06-11
US20090275126A1 (en) 2009-11-05
WO2005005635A2 (en) 2005-01-20
TW200513469A (en) 2005-04-16
EP1959014B1 (en) 2011-03-23
NO340438B1 (no) 2017-04-24

Similar Documents

Publication Publication Date Title
SI2272873T1 (sl) Protitelesa proti humanemu receptorju inzulinu podobnega rastnega faktorja i in njihova uporaba
ZA200507067B (en) Antibodies against human IL-21 receptor and uses therefor
HUS1600030I1 (hu) Humán anti-epidermális növekedési faktor receptor ellenanyag
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
SG155260A1 (en) Antibodies against human interleukin-13 and uses therefor
HK1091116A1 (en) Recombinant il-9 antibodies and uses thereof
HK1097859A1 (en) Anti-cd38 human antibodies and uses therefor -cd38
IL160998A0 (en) Human tissue factor antibodies
EP1699485A4 (en) ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
EP1570057A4 (en) AUTOCRINE GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS
ZA200606224B (en) Modified human growth hormone polypeptides and their uses
ZA200704926B (en) Modified human growth hormone
IL172510A0 (en) Antibodies and uses thereof
IL172511A0 (en) Specific human antibodies
SI1735348T1 (sl) Äśloveĺ ko anti-egfr protitelo
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
EP1589033A4 (en) ANTIBODY AND ITS USE
AU2003222225A8 (en) Receptors and membrane-associated proteins
IL166063A0 (en) Antibodies and uses thereof
AU2003277832A8 (en) Humanized tissue factor antibodies
HUP0402334A3 (en) Modified human growth hormone
AU2003272799A8 (en) Receptors and membrane-associated proteins
GB0226441D0 (en) Growth hormone variation in humans and their uses
EP1627888A4 (en) ANTIBODY AND ITS USE